Remove 2021 Remove Immune Response Remove Small Molecule
article thumbnail

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses

The Pharma Data

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

article thumbnail

Leveraging agonist antibodies to address immunological diseases

Drug Target Review

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.

Disease 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2021 Biotech IPOs Get Off to a Roaring Start

The Pharma Data

With this kind of a start, 2021 may be scorching. Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor. Other products include CLNB-049, a bispecific antibody against FLT3 and CD3 and CLN-619, a monoclonal antibody that simulates NK and T-cell responses.

article thumbnail

Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

The Pharma Data

In December 2021, Pfizer and BioNTech announced the companies would test a third 3 µg dose given at least two months after the second dose in children under age 5 and a third dose of the 10 µg formulation in children 5 to under 12 years of age. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.

article thumbnail

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera

The Pharma Data

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. The company was founded in 2021 by Stephen Kaldor, Ph.D., Executive Vice President, Research, Gilead Sciences. Qing Dong, Ph.D.,

article thumbnail

Advances in the Battle Against Autoimmune Disease

The Pharma Data

Small Molecule Inhibitors. NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. The FDA has set an action date of July 7, 2021. Oral, Small Molecules. Avacopan is an orally-administered selective complement 5a receptor inhibitor.

Disease 52
article thumbnail

Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

The Pharma Data

. Results from the PRECISION Study Expected in First Half of 2021. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. CHATHAM, N.J., 1 Noyce RS, et al.

Vaccine 40